Anavex Life Sciences (AVXL) Interest Coverage Ratio Growth (3y) (2019 - 2025)
Anavex Life Sciences (AVXL) Interest Coverage Ratio Growth (3y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | -42.41% |
| 2 | Nanobiotix | 1,905.61 Bn | 1,905.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,011.81 Bn | 1,011.81 Bn | - | - |
| 4 | BeOne Medicines | 467.29 Bn | 462.50 Bn | 1.35 Bn | 28.11% |
| 5 | Vertex Pharmaceuticals | 122.89 Bn | 115.65 Bn | 2.59 Bn | -6.89% |
| 6 | Regeneron Pharmaceuticals | 70.28 Bn | 61.53 Bn | 3.31 Bn | 79.27% |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.64 Bn | 34.63 Bn | 959.66 Mn | 40.09% |
| 10 | Anavex Life Sciences | 222.13 Mn | 90.38 Mn | - | 80.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 80.59% |
| Sep 30, 2025 | 89.64% |
| Jun 30, 2025 | -14.21% |
| Mar 31, 2025 | -31.60% |
| Dec 31, 2024 | -30.35% |
| Sep 30, 2024 | -29.44% |
| Jun 30, 2024 | -59.49% |
| Mar 31, 2024 | -45.55% |
| Dec 31, 2023 | -33.39% |
| Sep 30, 2023 | -43.30% |
| Jun 30, 2023 | -36.52% |
| Mar 31, 2023 | 18.61% |
| Dec 31, 2022 | 46.65% |
| Sep 30, 2022 | 12.06% |
| Jun 30, 2022 | 5.55% |
| Mar 31, 2022 | 47.39% |
| Dec 31, 2021 | 87.43% |
| Sep 30, 2021 | 38.81% |
| Jun 30, 2021 | 36.73% |
| Mar 31, 2021 | 33.19% |